Sermorelin Research for Anti-Aging
An evidence-based overview of research examining Sermorelin in the context of anti-aging. This page synthesizes findings from peer-reviewed literature.
Research Summary
Sermorelin has been extensively studied for age-related GH decline (somatopause). NIH research demonstrated that GHRH(1-29) reversed age-related decreases in GH and IGF-1 levels in elderly men, suggesting potential for addressing age-related hormonal changes.
A 20-week randomized trial in healthy older adults (55-87 years) showed GHRH raised IGF-1 and reduced percent body fat, without major adverse effects. These findings support the concept of GHRH therapy for age-related body composition changes.
Reviews of the somatotropic axis in aging note that the age-related decline in GH secretion is largely hypothalamic rather than pituitary in origin, providing a rationale for GHRH as an intervention that works by stimulating the pituitary to restore more youthful GH pulsatility.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Sermorelin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.